{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ODTX",
  "name": "Odyssey Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/ODTX/",
  "json_url": "https://frontierpicks.com/dossiers/ODTX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Odyssey Therapeutics' OD-001 re-rating depends on October expansion data sustaining its reported ulcerative-colitis efficacy. Confirmation requires comparable results retaining 27% remission and 61% response at UEG Week on October 17–20, before a weekly close below $23 invalidates the thesis.",
  "invalidation_trigger": "A weekly close below $23 invalidates the continuation thesis; separately, expansion-cohort results below 27% remission or 61% response under comparable definitions, or no updated efficacy by 2026-10-20, invalidate the October confirmation case.",
  "catalyst_date": "2026-09-23",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage with no product revenue; Q2 2026 GAAP net loss was $52.8M against $433.1M cash at 2026-06-30.",
    "Nasdaq debut 2026-05-08 at an $18 IPO price — roughly four months of listed history, so any technical level rests on a short record.",
    "A customary 180-day IPO lock-up from the 2026-05-07 pricing would come due around early November 2026; exact terms are in the S-1.",
    "OD-001's 27% remission / 61% response figures are from an uncontrolled Phase 2a monotherapy cohort; the first placebo-controlled read is guided to 2H 2027.",
    "Trades on Nasdaq as an ordinary US-listed common share; no ADR or dual-class structure disclosed in the IPO materials reviewed."
  ],
  "body_markdown": "## Current Thesis\n\nOdyssey Therapeutics' OD-001 re-rating depends on October expansion-cohort results sustaining its reported ulcerative-colitis efficacy, before a weekly close below $23 invalidates the market thesis. The company's 2026-06-17 update reported 27% clinical remission and 61% clinical response after 12 weeks in the uncontrolled Phase 2a monotherapy trial. These are preliminary observations; the cohort size and confidence intervals are missing from the evidence available for this refresh, preventing a claim about statistical reliability.\n\nThe inference is that the narrative is maturing — the adjusted close eased from $28.76 on 2026-09-04 to $24.38 on 2026-09-18, while the 14-day relative strength index (RSI) moved from 75.8 to 50.1. The company added a 2026-09-23 Stifel presentation in its September 16 announcement, but that announcement promises a management appearance rather than new clinical results. Renewed price strength and substantive expansion-cohort evidence would overturn the maturation assessment. [Company announcement, 2026-09-16](https://investors.odysseytx.com/news-releases/news-release-details/odyssey-therapeutics-participate-stifel-2026-virtual-immunology).\n\n## Bull Case\n\n- **An observable clinical hurdle.** Odyssey's 2026-06-17 update reported 27% remission and 61% response at 12 weeks. The October continuation case requires updated expansion-cohort efficacy to retain those benchmarks under comparable endpoint definitions; lower results would defeat that case.\n- **Funding extends beyond guided data.** The 2026-08-04 results release reported $433.1 million in cash and equivalents at 2026-06-30 and projected funding into the second half of 2028. That projection covers the company's then-guided second-half 2027 trial results; shortened runway guidance would invalidate this financing premise.\n- **Expansion treatment was complete.** Odyssey reported on 2026-08-04 that expansion-cohort treatment had finished, analyses were ongoing, and updated safety, efficacy and exploratory results had been accepted for an October oral presentation. A presentation without updated efficacy would leave the near-term confirmation case unmet.\n\n## Bear Case\n\n- **Comparative efficacy remains unresolved.** The uncontrolled results described on 2026-06-17 cannot establish benefit against placebo. The 2026-08-04 update placed Phase 2b monotherapy topline results in the second half of 2027; the October presentation cannot substitute for that controlled comparison.\n- **Losses qualify the funding claim.** The 2026-08-04 release reported a second-quarter 2026 net loss of $52.8 million under generally accepted accounting principles. The cash figure is dated June 30, and neither it nor the runway guidance establishes the September cash balance.\n- **Price confirmation has weakened.** The supplied adjusted series shows a $24.38 close on 2026-09-18, below the $28.76 close on 2026-09-04. A weekly close below $23 would end the continuation thesis even if management maintained its development timetable.\n\n## Setup & Price Structure\n\nThe measured September 18 readings are a $24.38 adjusted daily close, a three-month price increase of 30.2%, and a 14-day RSI of 50.1. These establish positive trailing performance with less momentum than the September 4 snapshot. They do not establish a completed base: intervening daily bars, moving-average values and comparable volume observations are absent from the supplied evidence.\n\nThe $23 threshold remains the research invalidation condition published on 2026-09-05; it is not presented as a verified support shelf. The September 4 close of $28.76 is a historical reference for recovery. No percentage distance or moving-average support is inferred from the available snapshots.\n\nCoverage provides an observable attention measure, rather than a positioning verdict. Benzinga reported H.C. Wainwright's initiation with a $44 analyst target on 2026-08-27, and Odyssey announced another investor appearance on 2026-09-16. Those events do not establish retail crowding, short-covering or institutional accumulation; dated ownership flows and comparable sentiment observations are missing.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-23 — Stifel management presentation.** Odyssey's September 16 release schedules the Virtual Immunology and Inflammation Forum appearance for 11:00 a.m. Eastern Time. It provides an opportunity to clarify trial timing; the release does not promise a clinical-data update. [Company announcement](https://investors.odysseytx.com/news-releases/news-release-details/odyssey-therapeutics-participate-stifel-2026-virtual-immunology).\n- **2026-09-26 — Conditional abstract availability.** United European Gastroenterology schedules ordinary accepted abstracts for release that day, with exceptions for top, late-breaking and press-related abstracts. OD-001's category is unverified, so this is a possible disclosure window rather than a confirmed company catalyst. [Organizer's publication policy](https://ueg.eu/press).\n- **2026-10-17 to 2026-10-20 — UEG Week.** The organizer confirms these meeting dates; the scientific congress runs October 18–20. Odyssey's August 4 update identifies an oral presentation of updated OD-001 results, but its exact session date remains unverified. Comparable expansion-cohort efficacy is the thesis test. [Organizer's schedule](https://ueg.eu/p/200).\n\n## What Would Change Our Mind\n\nFailure of the post-listing continuation structure is defined here as a weekly close below $23 in the adjusted daily-price series. The September 18 close of $24.38 remains above that threshold, but the available snapshots do not establish whether every intervening weekly close did.\n\nClinical confirmation also has a deadline: the October 17–20 meeting must deliver expansion-cohort efficacy that sustains the previously reported 27% remission and 61% response under comparable definitions. Lower rates, a material safety problem, or no updated efficacy by the meeting's conclusion would invalidate the October confirmation case. Meeting those descriptive benchmarks would still leave placebo-controlled efficacy unresolved.\n\n## Correlation Notes\n\nThe October OD-001 presentation identified in Odyssey's 2026-08-04 update makes this a single-company clinical catalyst thesis. The supplied September 18 evidence contains no matched sector-return series, so it supports no measured correlation claim or inference that a biotechnology group advance explains ODTX's performance. The price snapshots are too limited to distinguish company-specific repricing from broader market effects.",
  "first_seen": "2026-09-02",
  "last_analyzed": "2026-09-19T22:06:46+00:00",
  "last_synthesized": "2026-09-19",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}